Stock PHIO PHIO PHARMACEUTICALS CORP.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Phio Pharmaceuticals Corp.

Equities

PHIO

US71880W4024

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.682 USD -3.40% Intraday chart for Phio Pharmaceuticals Corp. +6.58% -10.26%
Apr. 22 Phio Pharmaceuticals Corp. Presents New Data About Its Lead Clinical Product Candidate, PH-762 CI
Apr. 16 Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
AQ
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
AQ
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
AQ
National Spotlight Features Phio’s Innovative RNAi Technology Platform
AQ
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
GL
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
AQ
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
AQ
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
AQ
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
AQ
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
AQ
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
GL
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
AQ
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
AQ
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
AQ
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
AQ
Phio CEO to Speak at Wainwright Conference in New York in September
AQ
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
AQ
Phio Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update
GL
Phio Pharmaceuticals Announces Closing of $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
PR
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PHIO Stock
  4. News Phio Pharmaceuticals Corp.
  5. Press Releases